Goldman Sachs’s OnKure Therapeutics OKUR Stock Holding History

Goldman Sachs’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,964	Closed	-$35.8K	–	6729
2025 Q2	$35.8K	Buy	+14,964	New	+$39.2K	﹤0.01%	5945
2024 Q4	–	Sell	-1,414	Closed	-$24K	–	6326
2024 Q3	$24K	Sell	1,414 -13,017	-90%	-$193K	﹤0.01%	5665
2024 Q2	$218K	Buy	14,431 +10,556	+272%	+$179K	﹤0.01%	5228
2024 Q1	$64.3K	Sell	3,875 -2,604	-40%	-$43K	﹤0.01%	5296
2023 Q4	$104K	Buy	6,479 +2,248	+53%	+$140K	﹤0.01%	5287
2023 Q3	$322K	Buy	+4,231	New	+$288K	﹤0.01%	4866

Other funds holding OKUR

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Goldman Sachs's OKUR Position: Q3 2025 in Review

Goldman Sachs sold out of OnKure Therapeutics (OKUR) in Q3 2025, closing a stake of 14,964 shares — an estimated $35.8K sold.

Goldman Sachs first reported a position in OKUR in Q3 2023 and held it in 6 quarters. The position peaked at $322K in Q3 2023. 42 funds tracked by Wall St. Rank hold OKUR as of Q3 2025.

Goldman Sachs reported no remaining OnKure Therapeutics position as of Q3 2025 after selling out during the quarter.
Goldman Sachs sold 14,964 OnKure Therapeutics shares in Q3 2025, an estimated $35.8K.
Goldman Sachs first reported a position in OnKure Therapeutics in Q3 2023 and held it in 6 quarters.
Goldman Sachs's OnKure Therapeutics position peaked at $322K in Q3 2023.
42 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.